Table 1. Characteristics of all patients.
| Characteristic | Total (n=92) | FS group (n=47) | FT group (n=45) | P |
|---|---|---|---|---|
| Age (years) | 0.301 | |||
| Median [range] | 60 [35–74] | 59 [39–72] | 61 [35–74] | |
| ≥65 | 18 (19.6) | 12 (25.5) | 6 (13.3) | |
| Sex | 0.537 | |||
| Female | 44 (47.8) | 21 (44.7) | 23 (51.1) | |
| Male | 48 (52.2) | 26 (55.3) | 22 (48.9) | |
| ECOG PS | 0.936 | |||
| 0–1 | 80 (87.0) | 41 (87.2) | 39 (86.7) | |
| 2 | 12 (13.0) | 6 (12.8) | 6 (13.3) | |
| Primary tumor site | 0.748 | |||
| Left colon | 61 (66.3) | 32 (68.1) | 29 (64.5) | |
| Right colon | 28 (30.4) | 13 (27.7) | 15 (33.3) | |
| Rectum | 3 (3.3) | 2 (4.2) | 1 (2.2) | |
| With liver metastasis | 53 (57.6) | 26 (55.3) | 27 (60.0) | 0.65 |
| Number of metastatic sites | 0.537 | |||
| ≤2 | 48 (52.2) | 26 (55.3) | 22 (48.9) | |
| ≥3 | 44 (47.8) | 21 (44.7) | 23 (51.1) | |
| Treatment line | 0.686 | |||
| 3 | 43 (46.7) | 21 (44.7) | 22 (48.9) | |
| ≥4 | 49 (53.3) | 26 (55.3) | 23 (51.1) | |
| KRAS mutation status | 0.631 | |||
| Wild type | 57 (62.0) | 28 (59.6) | 29 (64.4) | |
| Mutant | 35 (38.0) | 19 (40.4) | 16 (35.6) | |
| NRAS mutation status | 0.499 | |||
| Wild type | 84 (91.3) | 42 (89.4) | 42 (93.3) | |
| Mutant | 8 (8.7) | 5 (10.6) | 3 (6.7) | |
| BRAF mutation status | 0.368 | |||
| Wild type | 86 (93.5) | 45 (95.7) | 41 (91.1) | |
| Mutant | 6 (6.5) | 2 (4.3) | 4 (8.9) | |
| Whether previously treated with bevacizumab or cetuximab# | ||||
| Bevacizumab | 58 (63.0) | 28 (59.6) | 30 (66.7) | 0.076 |
| Cetuximab | 26 (28.3) | 16 (34.0) | 10 (22.2) | 0.208 |
Data are presented as n (%) if not otherwise specified. #, in the previous treatment, some patients in this study received bevacizumab, some patients received cetuximab, some patients received the above two targeted therapies, and some patients did not receive the two targeted therapies. FS, fruquintinib plus sintilimab; FT, fruquintinib plus TAS-102; TAS-102, trifluridine and tipiracil; ECOG PS, Eastern Cooperative Oncology Group performance status.